Effectiveness of semaglutide 2.4 mg vs. commercially available medications for chronic weight management in participants with obesity in a multi-employer setting in the US – a pragmatic clinical study (POSEY),
Role: Investigator,
Novo Nordisk Pharmaceuticals Inc.,
(10/2022)
Status: Approved
Internal
Transcriptomics of Pharmaceutically Assisted Lifestyle Management of Obesity Study (Ts)”,
Role: PI,
LLU School of Public Health,
(06/2023)
Status: Approved